This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
Haemonetics (HAE) Banks on Growing Hospital Arm, New Launches
by Zacks Equity Research
Haemonetics (HAE) is gaining from the newly completed limited market release of the new Express Plus technology with more than 60,000 real-world collections.
HAEPositive Net Change MEDPNegative Net Change HIMSNegative Net Change BTMDNegative Net Change
medical
Bristol Myers (BMY) Loses 20.5% YTD: Should You Retain or Fold?
by Ekta Bagri
Bristol Myers (BMY) faces an uphill struggle as top drugs face challenges. We advise investors to steer clear for the time being.
BMYPositive Net Change PFEPositive Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why
by Zacks Equity Research
Kazia (KZIA) surges after positive data from a phase II/III study on its lead pipeline drug in patients with glioblastoma. Based on this data, it plans to seek an accelerated nod from the FDA.
CGENNegative Net Change HRTXNegative Net Change KZIANegative Net Change ARQTNegative Net Change
biotechs medical
Verona (VRNA) Stock Surges 36% in the Past Month: Here's Why
by Zacks Equity Research
Verona Pharma (VRNA) surges on the recent FDA approval for its lead drug, which is the first inhaled COPD product with a novel mechanism of action in more than 20 years.
REGNNegative Net Change SNYPositive Net Change CGENNegative Net Change VRNAPositive Net Change
biotechs medical pharmaceuticals
Philips (PHG) Gains Despite Recall of SENSE XL Torso Coils
by Zacks Equity Research
Philips (PHG) issues an urgent recall of SENSE XL Torso coils (1.5T and 3.0T) due to heating risks during MRI scans.
PHGNegative Net Change UHSNegative Net Change DVAPositive Net Change DXCMPositive Net Change
medical medical-devices
Pacira (PCRX) Rises on Proposed Exparel Reimbursement Plan
by Zacks Equity Research
Pacira (PCRX) gains upon the inclusion of Exparel as one of only six qualifying non-opioid drugs to treat postsurgical pain in the proposed reimbursement rule, if adopted.
PCRXNegative Net Change CGENNegative Net Change ANVSNegative Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
The Zacks Analyst Blog Highlights Danaher, Morgan Stanley, Pfizer, Elite Pharmaceuticals and Oil-Dri
by Zacks Equity Research
Danaher, Morgan Stanley, Pfizer, Elite Pharmaceuticals and Oil-Dri are part of the Zacks top Analyst Blog.
MSNegative Net Change PFEPositive Net Change DHRNegative Net Change ELTPPositive Net Change ODCNegative Net Change
finance medical multi-sector-conglomerates pharmaceuticals
Best Momentum Stocks to Buy for July 12th
by Zacks Equity Research
IKNA, AVAH, and VEL made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 12, 2024.
VELPositive Net Change IKNANegative Net Change AVAHPositive Net Change
finance medical
Inovio (INO) Up as Lead Drug Gets Innovative Medicine Tag in UK
by Zacks Equity Research
Inovio (INO) soars 19% as its lead candidate, INO-3107, receives the innovative medicine tag under the U.K.'s Innovative Licensing and Access Pathway to treat recurrent respiratory papillomatosis.
INONegative Net Change CGENNegative Net Change ANVSNegative Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
UnitedHealth (UNH) Pre-Q2 Earnings: Healthy Buy or a Wait-&-See?
by Kaibalya Pravo Dey
UnitedHealth's (UNH) second-quarter earnings are likely to have benefited from higher premiums, driven by the expansion of its commercial membership base.
UNHPositive Net Change HUMNegative Net Change MOHPositive Net Change
earnings-preview hmo medical
Zacks Initiates Coverage of Elite Pharmaceuticals With Outperform Recommendation
by Debanjana Dey
Discover why Zacks rates Elite Pharmaceuticals as "Outperform", being the first on Wall Street to initiate coverage on the stock. Explore ELTP's strategic partnerships, financial health, and robust product pipeline.
ELTPPositive Net Change
medical
What Awaits Quest Diagnostics (DGX) in Q2 Earnings Release?
by Zacks Equity Research
Quest Diagnostics (DGX) is likely to have maintained its robust base business performance in the second quarter of 2024. However, nosediving COVID-19 testing revenues may limit growth.
DGXNegative Net Change HCAPositive Net Change HIMSNegative Net Change ENOVNegative Net Change
earnings medical medical-devices
Is It Wise to Retain Henry Schein (HSIC) in Your Portfolio Now?
by Zacks Equity Research
Robust acquisitions and a widespread distribution network bode well for Henry Schein's (HSIC) operations.
HSICNegative Net Change HAEPositive Net Change MEDPNegative Net Change HIMSNegative Net Change
medical medical-devices
Do Options Traders Know Something About HCA Healthcare (HCA) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to HCA Healthcare (HCA) stock based on the movements in the options market lately.
HCAPositive Net Change
medical
Implied Volatility Surging for AdaptHealth (AHCO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to AdaptHealth (AHCO) stock based on the movements in the options market lately.
AHCONegative Net Change
medical medical-devices
Thermo Fisher (TMO) Inks New Partnership for myeloMATCH Trial
by Zacks Equity Research
Thermo Fisher (TMO) announces a partnership with the National Cancer Institute for the myeloMATCH precision medicine umbrella trial to fuel research regarding new treatments for AML and MDS.
TMONegative Net Change HAEPositive Net Change MEDPNegative Net Change HIMSNegative Net Change
medical
4 GARP Stocks to Scoop up for Maximum Returns
by Shilpa Mete
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. BAP, BAH, HUBB and HCA are some stocks that hold promise.
HCAPositive Net Change BAHNegative Net Change BAPPositive Net Change HUBBPositive Net Change
business-services finance industrial-products medical
Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Neurocrine Biosciences (NBIX) stock based on the movements in the options market lately.
NBIXPositive Net Change
medical
Implied Volatility Surging for Labcorp (LH) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Labcorp (LH) stock based on the movements in the options market lately.
LHNegative Net Change
medical medical-devices
Zacks Investment Ideas feature highlights: Hims & Hers Health and Ero Copper
by Zacks Equity Research
Hims & Hers Health and Ero Copper are part of the Zacks Investment Ideas article.
ERONegative Net Change HIMSNegative Net Change
industrial-products medical
5 Must-Buy Efficient Stocks to Enrich Your Portfolio
by Santanu Roy
Invest in companies like Daktronics (DAKT), Hess (HES), Advanced Drainage Systems (WMS), Apogee Enterprises (APOG) and GENEDX HOLDINGS (WGS) to make the most of higher efficiency levels.
HESNegative Net Change WMSNegative Net Change APOGNegative Net Change DAKTNegative Net Change WGSNegative Net Change
computers construction industrial-products medical oil-energy
New Strong Buy Stocks for July 12th
by Zacks Equity Research
USAC, NHYDY, APOG, IKNA, and CRGY have been added to the Zacks Rank #1 (Strong Buy) List on July 12, 2024.
APOGNegative Net Change USACNegative Net Change NHYDYNegative Net Change IKNANegative Net Change CRGYNegative Net Change
industrial-products medical oil-energy
Here's Why You Should Add DaVita (DVA) to Your Portfolio
by Zacks Equity Research
DaVita's (DVA) strength in its kidney care raises optimism about the stock.
UHSNegative Net Change ISRGPositive Net Change DVAPositive Net Change DXCMPositive Net Change
medical medical-devices
Masimo (MASI) Gets Non-Binding Offer for Consumer Business
by Zacks Equity Research
Masimo (MASI) gets an acquisition offer for its consumer business from an undisclosed entity. The deal is likely to close later in 2024.
UHSNegative Net Change DVAPositive Net Change MASINegative Net Change DXCMPositive Net Change
medical medical-devices
New Strong Sell Stocks for July 12th
by Zacks Equity Research
CSIQ, FMC and INDV have been added to the Zacks Rank #5 (Strong Sell) List on July 12, 2024.
CSIQNegative Net Change FMCNegative Net Change INDVNegative Net Change
medical